Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shanghai Argo Biopharma Closes $41 Million Series A+ Round for RNAi Therapies

publication date: Nov 6, 2023

Argo Biopharmaceutical, a Shanghai RNAi company, raised $41 million in a Series A+ round to develop next-gen RNAi drugs for cardiovascular, congenital and immune system conditions. The company, founded by returnees, has experience in RNAi drug development including bioinformatics and nucleic acid sequence design, chemical modification, GalNAc coupling technology, extrahepatic delivery technology development, and oligonucleotide CMC. The financing was led by CS Capital, with participation from Huagai Capital and existing investor Trinity Innovation Fund. More details....

Share this with colleagues:  

 



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here